It’s part of Glooko’s push to make its app and iPhone connecting cable compatible with a variety of glucometers, according to mobihealthnews.
Palo Alto-based Glooko’s Logbook app connects 17 different devices to the iPhone, the website reported, including Bayer’s Contour Next EZ and Contour XT and the Arkray Glucocard 01 and Glucocard Vital devices.
Wal-Mart, which launched its glucometers in July, is making a concerted push to get in on the healthcare market. In 2009 the world’s largest retailer announced plans for an electronic medical records system.
Freedom Meditech takes out $2M credit line
Freedom Meditech said it inked a $2 million line of credit from Silicon Valley Bank,saying it’s getting ready to "ramp up manufacturing and distribution of the company’s ClearPath DS-120 Lens Fluorescence Biomicroscope, currently under regulatory review in the U.S. and European Union." Freedom Meditech submitted its first round of paperwork to the FDA for the device last year.
NeuroMetrix wins NASDAQ reprieve
NeuroMetrix (NSDQ:NURO) won a 6-month reprieve from the NASDAQ stock exchange to regain compliance with the exchange’s minimum share price requirement. NASDAQ first warned the company in 2010 that it was at risk for a de-listing, prompting a 1-for-6 reverse stock split the next year.
- Abiomed (NSDQ:ABMD): TheStreet Ratings upgrades from "hold" to "buy" rating, sets $18 price target.
- Baxter (NYSE:BAX): Deutsche Bank downgrades from “buy” to “hold” rating, sets $63 price target.
- Becton Dickinson & Co. (NYSE:BDX): Piper Jaffray reissues "neutral" rating, $77 price target.
- Hospira (NYSE:HSP): Leerink Swann maintains “market perform” rating, lowers price target from $35-36 to $33-34, lowers estimates.
- Medtronic (NYSE:MDT): UBS AG reaffirms "buy" rating.
- Shire (NSDQ:SHPGY): Jefferies upgrades from "hold" to "buy" rating, increases price target from $100 to $117.